54
Participants
Start Date
December 31, 2012
Primary Completion Date
January 31, 2013
Study Completion Date
January 31, 2013
a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).
Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
Teva Investigational Site 10471, Austin
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY